The robotic assisted surgery systems market size is expected to increase from USD 11.26 billion in 2025 to USD 12.76 billion in 2026 and reach USD 23.86 billion by 2031, growing at a CAGR of 13.33% over 2026-2031. This report is Segmented by Product Type (System [Surgical Robot, Navigation System], Consumables & Accessories, and Software & Services), Application (Gynecological, and More), End User (Hospitals, Ascs, Specialty Clinics, and Academic Institutes), and Geography (North America, Europe, Asia-Pacific, MEA, and South America). Market Forecasts are Provided in Terms of Value (USD).
Instrument consumables scale directly with volume. Intuitive’s installed base delivered 1.9 million procedures in 2025, translating into roughly USD 5.7 billion instrument revenue. Open-architecture platforms such as Hugo RAS promote third-party integration, while CMR Surgical’s Versius lowers the entry price by 40%, accelerating adoption in mid-tier facilities. Navigation robots like Globus Medical’s ExcelsiusGPS addressed spinal screw accuracy, fueling double-digit procedure growth in 2025.
Asia-Pacific is forecast to grow at a 14.65% CAGR through 2031, driven by cost-competitive domestic makers. MicroPort’s Toumai, priced at CNY 8 million (USD 1.1 million), enabled penetration into Tier 2‒3 Chinese cities. Japan’s Medicaroid logged 85 hinotori installations by end-2025 after national insurance extended coverage to robotic gastric resection, pushing volumes up 34% year-on-year. India remains attractive, as CMR Surgical plans to place Versius in 12 hospitals by late 2025, tapping a self-pay market sensitive to upfront pricing. South Korea and Australia support adoption through subsidies and fast-track software approvals, respectively.
Europe faces slower uptake under the Medical Device Regulation and mixed reimbursement. Germany’s statutory insurance covers robotic prostatectomy, but the U.K.’s National Health Service restricts use to complex cases after NICE’s 2024 cost-effectiveness ruling. Medtronic’s Hugo RAS secured 42 European installations by late 2025, targeting private hospitals in France and Italy where fee-for-service models finance innovation. In the Middle East, the United Arab Emirates equipped eight public hospitals with robots between 2024-2025, while Brazil’s pilot reimbursement in São Paulo performed 1,200 procedures in its first year.
Global Robotic Assisted Surgery Systems Market Trends and Insights
Technological Advancements in Surgical Robotics
Continuous hardware and software iterations are shrinking performance gaps with open surgery. The FDA cleared Intuitive Surgical’s da Vinci 5 in March 2024, enabling real-time haptic feedback that helps surgeons differentiate tissue planes. Machine-learning navigation modules lowered positive margin rates in robotic prostatectomy by 18% in a 2025 multi-center study published in The Lancet Digital Health. Level-3 autonomous functions now account for 6% of cleared devices, indicating regulatory acceptance of conditional autonomy. Modular designs, such as CMR Surgical’s Versius, allow deployment in operating rooms 30% smaller than those of legacy multi-port platforms, widening the addressable facilities. These features collectively reinforce the robotic-assisted surgery systems market growth outlook.Growing Preference for Minimally Invasive Procedures
Payers and patients increasingly favor shorter stays and faster returns to work. The American Association of Gynecologic Laparoscopists reported that robotic hysterectomy accounted for 57% of benign cases at U.S. academic centers in 2025, up 9 percentage points in 2 years, citing lower blood loss and faster discharge. Stryker’s registry of 8,400 total knee arthroplasties found 92% patient satisfaction at 12 months when the Mako robot was used, versus 84% with manual tools. Ambulatory surgery centers secure 15%-20% higher reimbursement than laparoscopy, yet only 8% had installed a robot by mid-2025 due to capital hurdles. Vendors are introducing leasing plans and single-port designs to close this gap, a move expected to accelerate the penetration of robotic-assisted surgery systems.High Capital and Operational Expenditure
A da Vinci Xi costs roughly USD 2 million, with annual service contracts of USD 150,000-200,000 and disposable instruments adding USD 2,000-3,500 per case. Health Affairs calculated a 7.2-year payback for a 400-bed hospital performing 300 cases annually under Medicare tariffs, exceeding the typical 5-year hurdle rate. Rural U.S. hospitals cite capital limits as the top adoption barrier, and exclusive instrument tie-ins prompted an ongoing Federal Trade Commission probe in 2024 that alleges 30%-40% price inflation. Import duties and currency swings further constrain emerging-market uptake, capping near-term robotic assisted surgery systems market size in those regions.Other drivers and restraints analyzed in the detailed report include:
- Increasing Geriatric Patient Base and Disease Incidence
- Expanding Clinical Evidence Supporting Robotic Outcomes
- Stringent and Fragmented Regulatory Requirements
Segment Analysis
Systems captured 57.84% of robotic assisted surgery systems market share in 2025, underscoring the capital-intensive nature of platform rollout. Nevertheless, Software & Services is projected to surge at a 15.65% CAGR through 2031 as hospitals prioritize training simulators, AI navigation, and analytics dashboards that deepen recurring revenue. The robotic assisted surgery systems market size for Software & Services is expected to expand faster than Systems, supported by Medtronic’s Touch Surgery Enterprise, which booked USD 180 million in 2025 recurring sales across 420 hospitals.Instrument consumables scale directly with volume. Intuitive’s installed base delivered 1.9 million procedures in 2025, translating into roughly USD 5.7 billion instrument revenue. Open-architecture platforms such as Hugo RAS promote third-party integration, while CMR Surgical’s Versius lowers the entry price by 40%, accelerating adoption in mid-tier facilities. Navigation robots like Globus Medical’s ExcelsiusGPS addressed spinal screw accuracy, fueling double-digit procedure growth in 2025.
Complete Report Scope:
- By Product Type
- System
- Surgical Robot
- Navigation System
- Consumables & Accessories
- Software & Services
- System
- By Application
- Gynecological Surgery
- Cardiovascular Surgery
- Neurosurgery
- Orthopedic Surgery
- Laparoscopy / General Surgery
- Urology
- Thoracic Surgery
- Otolaryngology (ENT)
- Other Applications
- By End User
- Hospitals
- Ambulatory Surgery Centers
- Specialty Clinics
- Academic & Research Institutes
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America commanded 43.54% share in 2025, sustained by dense installed bases and dedicated CPT codes that shield hospital margins. The United States alone had performed roughly 12 million cumulative da Vinci procedures by January 2026, demonstrating entrenched use. Canada diverted CAD 150 million (USD 110 million) in 2025 to deploy robots in 18 community hospitals, targeting reductions in oncology wait times. Mexico’s social security system installed 14 platforms in 2024 to curb complications from open surgery among diabetic patients.Asia-Pacific is forecast to grow at a 14.65% CAGR through 2031, driven by cost-competitive domestic makers. MicroPort’s Toumai, priced at CNY 8 million (USD 1.1 million), enabled penetration into Tier 2‒3 Chinese cities. Japan’s Medicaroid logged 85 hinotori installations by end-2025 after national insurance extended coverage to robotic gastric resection, pushing volumes up 34% year-on-year. India remains attractive, as CMR Surgical plans to place Versius in 12 hospitals by late 2025, tapping a self-pay market sensitive to upfront pricing. South Korea and Australia support adoption through subsidies and fast-track software approvals, respectively.
Europe faces slower uptake under the Medical Device Regulation and mixed reimbursement. Germany’s statutory insurance covers robotic prostatectomy, but the U.K.’s National Health Service restricts use to complex cases after NICE’s 2024 cost-effectiveness ruling. Medtronic’s Hugo RAS secured 42 European installations by late 2025, targeting private hospitals in France and Italy where fee-for-service models finance innovation. In the Middle East, the United Arab Emirates equipped eight public hospitals with robots between 2024-2025, while Brazil’s pilot reimbursement in São Paulo performed 1,200 procedures in its first year.
List of Companies Covered in this Report:
- Asensus Surgical
- Brain Lab
- CMR Surgical
- Globus Medical
- Intuitive Surgical
- Johnson & Johnson (Ethicon/Auris)
- Medical Microinstruments (MMI)
- Medicaroid
- Medtronic
- Meere Company
- MicroPort MedBot
- Renishaw
- Siemens Healthineers (Corindus Vascular)
- Smiths Group
- Stryker
- Think Surgical
- Titan Medical
- Zimmer Biomet
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Asensus Surgical
- Brainlab
- CMR Surgical
- Globus Medical
- Intuitive Surgical
- Johnson & Johnson (Ethicon/Auris)
- Medical Microinstruments (MMI)
- Medicaroid
- Medtronic
- Meere Company
- MicroPort MedBot
- Renishaw
- Siemens Healthineers (Corindus Vascular)
- Smith & Nephew
- Stryker Corporation
- Think Surgical
- Titan Medical
- Zimmer Biomet
